| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |